Loading your page…
Loading your page…
Published by American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines · ACC/AHA Class of Recommendation and Level of Evidence
This guideline provides comprehensive, evidence-based recommendations for the diagnosis and management of atrial fibrillation. It emphasizes a new staging classification, lifestyle and risk factor modifications, stroke risk assessment, and strategies for both rate and rhythm control.
Key Takeaways
Introduced a new classification of AF by stages as a disease continuum; emphasized early rhythm control and lifestyle risk factor modification (LRFM); upgraded catheter ablation to a Class 1 recommendation for first-line therapy in select patients and those with HFrEF; upgraded left atrial appendage occlusion (LAAO) devices to a Class 2a recommendation; provided updated guidance on device-detected AF and AF discovered during acute medical illness/surgery.
In patients with newly diagnosed AF, a transthoracic echocardiogram to assess cardiac structure, laboratory testing to include a complete blood count, metabolic panel, and thyroid function, and when clinical suspicion exists, targeted testing to assess for other medical conditions associated with AF are recommended to determine stroke and bleeding risk factors, as well as underlying conditions that will guide further management.
In patients with newly diagnosed AF, protocolized testing for ischemia, acute coronary syndrome (ACS), and pulmonary embolism (PE) should not routinely be performed to assess the etiology of AF unless there are additional signs or symptoms to indicate those disorders.
Patients at increased risk of AF should receive comprehensive guideline-directed LRFM for AF, targeting obesity, physical inactivity, unhealthy alcohol consumption, smoking, diabetes, and hypertension.
Patients with AF should be evaluated for their annual risk of thromboembolic events using a validated clinical risk score, such as CHA2DS2-VASc.
For patients with AF and an estimated annual thromboembolic risk of ≥2% per year (eg, CHA2DS2-VASc score of ≥2 in men and ≥3 in women), anticoagulation is recommended to prevent stroke and systemic thromboembolism.
In patients with AF who do not have a history of moderate to severe rheumatic mitral stenosis or a mechanical heart valve, and who are candidates for anticoagulation, DOACs are recommended over warfarin to reduce the risk of mortality, stroke, systemic embolism, and ICH.
In patients with AF with rapid ventricular response who are hemodynamically stable, beta blockers or nondihydropyridine calcium channel blockers (verapamil, diltiazem; provided that EF >40%) are recommended for acute rate control.
In selected patients (generally younger with few comorbidities) with symptomatic paroxysmal AF in whom rhythm control is desired, catheter ablation is useful as first-line therapy to improve symptoms and reduce progression to persistent AF.
Clinical Topic
Atrial Fibrillation
Objectives
Provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.
Target Patient Population
Patients with or at risk of developing atrial fibrillation
Diagnostic Criteria
Irregular R-R intervals (when atrioventricular conduction is present), absence of distinct P waves, and irregular atrial activity (fibrillatory waves) documented by ECG.
Target Providers
Therapeutic Area
Cardiovascular DiseaseGuideline Scope
Care Settings
Special Populations
System: ACC/AHA Class of Recommendation and Level of Evidence
Evidence Levels
Recommendation Strength
Contraindications
Monitoring Guidance
Includes routine INR monitoring for warfarin, DOAC laboratory monitoring based on renal and hepatic function, and QT interval/electrolyte monitoring for specific antiarrhythmic drugs like dofetilide, ibutilide, and sotalol.
Difficulty
advanced
Exam Relevance
Learning Paths